Socio-economic Determinants for Acceptance and Choice of Biological Treatment

NCT04369651 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 117

Last updated 2020-05-01

No results posted yet for this study

Summary

This was a cross-sectional study conducted at National center for rheumatic diseases, Nepal on SpA patient refractory to initial treatment with conventional anti rheumatic drugs. Patients taking TNFi (tumor necrosis factor inhibitor- adalimumab or etanercept) or tofacitinib were included. Baseline demographic, socio-economic, clinical data were recorded.

Conditions

  • Spondyloarthritis

Sponsors & Collaborators

  • National Center for Rheumatic Diseases, Nepal

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-06-01
Primary Completion
2019-12-31
Completion
2019-12-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04369651 on ClinicalTrials.gov